Transport insiders are sounding the alarm over the Mount Isa-Townsville railway, which they say is so focused on squeezing ...

Eli Lilly has signed another bolt-on deal to bulk up its pipeline, this time paying $47.5 million upfront for rights to a non-opioid analgesic drug developed by US biotech Centrexion Therapeutics.